Drugs / Loxenatide
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05172999 | Jan 2022 → Dec 2025 | atypical endometrial hyperplasia, infertility disorder, obesity disorder | Fudan University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06825182 | Nov 2024 → Aug 2025 overdue | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06217887 | May 2020 → Feb 2024 | cognitive disorder, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Loxenatide | “Loxenatide” NCT06825182 ↗ |
| Action | Activate | “GLP-1 receptor agonist (GLP-1RA)” NCT05172999 ↗ |